The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | How to manage iron deficiency to improve outcomes in patients with polycythemia vera
Marta Sobas, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, provides her recommendations for managing iron deficiency in patients with polycythemia vera (PV), outlining that this is typically driven by exaggerated erythropoiesis and repeated phlebotomy. Dr Sobas explains that iron supplementation can raise the need for phlebotomy; however, new agents such as rusfertide may act as a replacement, potentially resolving this issue. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
